Aclarion, Inc. (ACON)

US — Healthcare Sector
Peers:   EUDA  FOXO  AUGX  ETAO  AKLI  HCTI  MGRX  HSTM  NRC  FORA 

Automate Your Wheel Strategy on ACON

With Tiblio's Option Bot, you can configure your own wheel strategy including ACON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ACON
  • Rev/Share 0.0249
  • Book/Share 7.1938
  • PB 0.9258
  • Debt/Equity 0.0
  • CurrentRatio 21.6833
  • ROIC -0.3631

 

  • MktCap 3878591.0
  • FreeCF/Share -2.6449
  • PFCF -0.6685
  • PE -2.2032
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.269

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Aclarion Announces Texas Back Institute as New CLARITY Trial Site
ACON
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic …

Read More
image for news Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
ACON
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA.

Read More
image for news Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
ACON
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low …

Read More
image for news Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
Aclarion Provides Shareholder Update
ACON
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review.

Read More
image for news Aclarion Provides Shareholder Update
Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
ACON
Published: March 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey.

Read More
image for news Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
ACON
Published: February 28, 2025 by: MCAP MediaWire
Sentiment: Neutral

Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo.

Read More
image for news Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
ACON
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Special Meeting of Stockholders (the “Special Meeting”) scheduled for February 28, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission (the “SEC”) on February 3, 2025.

Read More
image for news Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
ACON
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the 2025 Spine Summit.

Read More
image for news Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
ACON
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

Recent Notice of Allowance is for Aclarion's 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc Patent will expand Aclarion's proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body BROOMFIELD, Colo., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, …

Read More
image for news Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

About Aclarion, Inc. (ACON)

  • IPO Date 2022-04-22
  • Website https://www.aclarion.com
  • Industry Medical - Healthcare Information Services
  • CEO Mr. Brent Ness
  • Employees 5

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.